» Articles » PMID: 11573023

Enhancing Recovery in Coronary Heart Disease (ENRICHD) Study Intervention: Rationale and Design

Overview
Journal Psychosom Med
Specialty Psychiatry
Date 2001 Sep 27
PMID 11573023
Citations 59
Affiliations
Soon will be listed here.
Abstract

Objective: Depression and low social support are risk factors for medical morbidity and mortality after acute MI. The ENRICHD study is a multicenter, randomized, controlled clinical trial of a cognitive-behavioral treatment for depression and low social support in post-MI patients. A total of 2481 patients were recruited (26% with low social support, 39% with depression, and 34% with low social support and depression). Our objective is to describe the rationale, design, and delivery of the ENRICHD intervention.

Methods: Key features of the intervention include the integration of cognitive-behavioral and social learning approaches to the treatment of depression and a diverse set of problems that can contribute to low social support; rapid initiation of treatment after MI; a combination of individual and group modalities; adjunctive pharmacotherapy for severe or intractable depression; training, certification, and supervision of therapists; and quality assurance procedures.

Results: The trial's psychosocial and medical outcomes will be presented in future reports.

Conclusions: The ENRICHD protocol targets two complex psychosocial risk factors with a multifaceted intervention, which is delivered in an individualized manner to accommodate a demographically, medically, and psychiatrically diverse patient population. Additional research will be needed to identify optimal matches between patient characteristics and specific components of the intervention.

Citing Articles

Cross-cultural adaptation and psychometric evaluation of the Thai version of the Enhancing Recovery in Coronary Heart Disease Social Support Inventory in individuals with chronic illnesses.

Phetrnui S, Suwanno J, Chiaranai C, Bunsuk C, Koson N, Kumanjan W Int J Nurs Sci. 2025; 12(1):65-73.

PMID: 39990982 PMC: 11846552. DOI: 10.1016/j.ijnss.2024.12.013.


The Brain-Heart Axis: An Umbrella Review on Impact of Psychiatric Disease on Incidence, Management, and Outlook of Cardiovascular Disease.

Mazza M, Biondi-Zoccai G, Lisci F, Brisi C, Sfratta G, Rossi S Life (Basel). 2024; 14(8).

PMID: 39202662 PMC: 11355298. DOI: 10.3390/life14080919.


Association of social support and health status outcomes in peripheral artery disease.

Callegari S, Romain G, Cleman J, Scierka L, Peri-Okonny P, Spertus J J Vasc Surg. 2024; 80(6):1824-1835.e7.

PMID: 39151740 PMC: 11585422. DOI: 10.1016/j.jvs.2024.08.010.


External Validation of a Machine Learning Model for Schizophrenia Classification.

He Y, Sakuma K, Kishi T, Li Y, Matsunaga M, Tanihara S J Clin Med. 2024; 13(10).

PMID: 38792511 PMC: 11121762. DOI: 10.3390/jcm13102970.


Association Between Pharmacy Proximity With Cardiovascular Medication Use and Risk Factor Control in the United States.

Zheutlin A, Sharareh N, Guadamuz J, Berchie R, Derington C, Jacobs J J Am Heart Assoc. 2024; 13(5):e031717.

PMID: 38390820 PMC: 10944071. DOI: 10.1161/JAHA.123.031717.